cancer, lung, non-small-cell, advanced
DISEASE INTERVENTION COMPARISON RESULTS
N Engl J Med. 2010 Jun 24;362(25):2380-8 Randomized Controlled Trial, Multicenter Study
IN cancer, lung, non-small-cell, advanced The Use of
gefitinib, EGFR tyrosine kinase inhibitor
As Treatment, Acute
Is better Than
carboplatin-paclitaxel chimiotherapy
To improve survival: 30 months gefitinib VS 24 carboplatin. Gefitinib had also less severe adverse effects.
N Engl J Med. 2010 Aug 19;363(8):733-42 Randomized Controlled Trial, Multicenter Study
IN cancer, lung, non-small-cell, advanced The Use of
early palliative care, integrated with standard oncologic care
As Treatment, Chronic
Is better Than
standard oncologic care alone
To improve quality of life and to improve survival (12 months early palliative VS 9 months standard) despite receiving less agressive end-of-life care.